Bio-Path (BPTH) provided an update from the company’s ongoing Phase 1/1b clinical trial evaluating BP1002 for the treatment of ...
15don MSN
Chemicals and materials maker DuPont (DD) is rallying 7% after posting stronger-than-expected fourth quarter financial results today and providing earnings per share guidance for the current full year ...
It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback